Okay guys we got Fabio on the line. Hey how's it going? Hey Fabio how you doing? It's Rich. Pleasure to meet you Fabio. We are live right now on YouTube. Okay awesome. Hi everyone. Yeah. Yeah so uh super excited to speak to you today and the stock is doing well. Congratulations stock's having a nice day. Oh thank you. Thank you very much. That's 44 cents in Canada right now. Up 12% and I believe it's at 33 cents up 10% in America. So Ph. R. M. Symbol Guys in Canada. Ph. R. R. F. is the symbol in America for anybody who's watching. Fabio I have a couple questions for you. Are you ready? Sure. Yeah absolutely. Awesome. So Fabio first and foremost can you tell us about Pharma Third Inc. and how it has evolved from when you founded the company? Yeah absolutely. So first of all I'm going to thank you for having this interview and to your audience. Thank you for joining and listening and about Pharma Third Inc. and its exciting developments in the psychedelics pharmaceutical space. So I'll just go a little bit about the background of the company. I founded Pharma Third Inc. and Pharma Third Inc. is focused on the next generation transdermal delivery of psychedelics pharmaceuticals with a specific focus on ketamine to treat mental health, neurological and pain disorders. Our patent portfolio consists of 19 patents and patent applications that cover the uses of ketamine, psilocybin and then the unique formulations of ketamine that is ready for a clinical trial and as well as a proprietary micro needle delivery patch or technology to deliver these psychedelic pharmaceuticals. So for instance our micro needle patch which would be applied to say your arm for a safe and effective delivery of these psychedelics and the problem in today which we're trying to solve is that all psychedelic therapies comes in several delivery forms such as nasal spray, intravenous injection or even oral ingestion such as psilocybin the actual mushroom as an edible. Now as in the case of psilocybin or ketamine a patient would need to be treated say in a hospital or clinic under supervision of say one or two healthcare providers for several hours and even up to even eight hours per session to monitor any side effects of these drugs would have such as hallucination, nausea, amnesia and whatnot just to make sure that they're okay. Our approach is deliver these psychedelic pharmaceuticals such as ketamine in a micro needle patch and actually a prototype you can even view it on our website or on our investor deck or corporate deck that is formulating a way to significantly reduce the side effects what we call the psychomimetic effects of these drugs such as hallucination, amnesia and nausea that's allowing the patient to treat their say their mental health such as depression safely and conveniently at home at their leisure with the way of having it being effective. Wow that's great sounds like yeah so really yeah absolutely like in essence our goal is to change the way psychedelics are used to treat these unmet medical needs with our particular focus which are lead programs in Parkinson's disease and depression. Wow now you mentioned it a little bit what are your main focuses on Pharmacere Inc for the first half of 2021 and some of the milestones the company has set to achieve? Yeah seeing that we're a focused psychedelic biotech company we are aiming to initiate two FDA phase two human clinical trials with ketamine in the treatment of Parkinson's disease as well as in depression and also further we're going to have research results and progress of our micro needle patch for a number of these psychedelic pharmaceuticals for actually the micro dosing program that we have for SO5 and DMT and DNA even LSD and combinations thereof and what's also significant which is part of the company though we're actually selling our SO5 and part of our program which we actually found that's what the companies which we founded on to revive therapeutics and we'll can discuss that later on if you'd like that will provide non-dilutive funding for the company to advance its clinical development with ketamine and its micro dosing strategy all under the umbrella of our micro needle delivery technology so it's really exciting for us over the next over the next six months. Yeah this is great and it's funny because I found your about your company through one of our members one of our members like you got to put this company on your watch list I had never heard of your company before a lot of our members are hearing about it now for the first time and a lot of our members when I started talking about the fact that we were going to interview this morning started to buy started to buy oh they just started to buy it so they started getting at 40 cents 41 cents 42 cents they're already up and it's exciting to hear from you directly so that they get a better idea of where the company's going so in knowing that the psychedelic space is growing every day very quickly we've seen mind medicine 10x and I was one of the first ones ever to interview mind medicine when they were 30 cents and they went through this little dull period for like about six months where they didn't do anything and then out of nowhere it went from 30 cents to four bucks that's the stock market I try to explain this to people I was like you know whenever stocks don't go up there's this thing and I always I joke about it but it's really real it's like when stocks are going down people are panicking but that's really the best time to buy and when stocks are up people are beating their chest talking about how great they are that's the best time to sell it's so hard to teach people to think that way because everybody does the opposite right people are in like people and it's this is why I have a trading club people chase green what I do is I teach them to chase the red because that's how you buy something on sale it's the same thing that Warren Buffett does like when when Warren Buffett buys a stock he doesn't chase it at all-time highs he buys them when they're really beating down a lot of people forget when Goldman Sachs during the last major correction in 2008 was in major trouble Warren Buffett wrote a huge check for $500 million when they were dirt cheap he's made billions of dollars on that one investment that's how investors make money you buy low you wait allow the company to grow mature build revenue and when the companies had a major catalyst and they explode that's when we tell our members take profits this is a great trading strategy but for some reason so many people do it backwards now the psychedelic space like we said has been growing every day new companies are starting to emerge can you tell us what sets farm with their ink apart from the rest there's so many mind medicines out there everyone wants a piece of this sector what makes you guys unique yeah absolutely like I mean there are a number of psychedelic companies are focused on either producing their own drugs such as psilocybin in their whether it be a say a biophinsetic way or the other proprietary processes so they can be able to conduct their own research with their own supply if you will and also supply the market whether it's the clinical research or even even for the market itself when they say the regulations become more right friendly or deregulated if you will so you have that kind of bucket of companies there and then you have these other bucket of companies that have the physical asset strategy where they're opening or expanding these psychedelic based clinics such as ketamine clinics and whatnot whether they're opening new ones or doing some sort of roll-up strategy then you have that kind of bucket of companies and both strategy are fantastic for the industry and they serve the gaps of the market today and I'm a fan of all those types of companies are trying to do something in this space because we all have this common goal is to you know bring psychedelic pharmaceuticals to the forefront because basic current treatments are not working but however my opinion you know and maybe it's just being a bias because I come from a biotech background is that I believe the largest market opportunity is being a pure play biotech pharma that's focused on developing psychedelic pharmaceuticals for the for FDA approval so like the largest player in the space such as MindMed such as Compass Pathway so MindMed with their LSD and even MD&A and combinations they're up Compass Pathway with their psilocybin all going directly to the FDA approval then you have J&J a monster pharmaceutical company that recently had their ketamine nasal spray for treatment of depression all that biotech pharmaceutical based strategy and including in the mix is us you know with our focus on investing in psychedelic pharmaceuticals as a prescription for FDA approvals so we have for instance our own ketamine formulation which is a combination and then an IP in finding novel uses and delivering these psychedelics in a unique way that is safe pain-free as well as convenient so that can be taken at home so specifically our focus is commercialized a novel formation of ketamine in a proprietary needle patch that would offer these safe and effective convenient and also as a compliant way to treat the mental health such as depression or PTSD neurological disorders such as Parkinson's disease and even pain such as neuropathic or even post-operative say after surgery without the need for restricted oversight though by a healthcare professional say at a hospital or clinic so again we're going back to our thesis or our mission if you will is that we're changing the way our psychedelics are being used to treat these significant unmet medical needs with the psychedelic pharmaceuticals so that's how we kind of differentiate ourselves in this whole arena of players in the space that's great now you mentioned a little bit earlier in the interview that you guys are partnering with revive therapeutics can you please go through the partnership with us and how it benefits the company yeah so as you know farm affairs discussed that we made decision to focus our resources in commercializing ketamine for Parkinson's and depression all other types of same mental health disorders we really literally have I call it a pipeline in a patch if you will so that ketamine a micro needle patch can be used for a number of these indications and which of course are all you know multi-billion dollar market opportunities and they have significant unmet medical needs treatments right now do not work so since our inception though we were focused on developing unique or novel uses of psilocybin for specifically in neurological sources such as stroke and traumatic brain injury as well as even file patents on psilocybin to be used for certain cancer indications as an adjunct to current cancer treatments and in addition we also have an IP that combination of psilocybin with other FDA approved drugs that could potentially be used for neurological diseases now seeing that revive is building a like a one-of-a-kind psilocybin program and so and more specifically in with the not only for psychedelics but psilocybin itself with their development of an oral fin or like that listerine type fin film product and psilocybin and they're developing with the University of Wisconsin as well as they're developing their own biosynthetic version of psilocybin in partnership with North Carolina State University and they're also doing a clinical study for psilocybin in them in the for the treatment of methamphetamine methamphetamine use disorders and that's being done at the University of Wisconsin so they have this kind of like really a broad or specialized I should say psilocybin program and the decision if you say to park our psilocybin development with revive and leverage their infrastructure is a no brainer win-win outcome for both for both companies so it made sense to kind of you know really leverage that asset take it to the next level in a in a in a home if you will that has a focus where we can focus on our core which is delivering ketamine for all these other developed indications now it's vital when you're looking into a company that the company has a strong management team can you tell us a little bit about the Pharma Thayer team and what each member and the key members bring to the table yeah absolutely and you're right because it's the ability to execute at the end of the day right and now one of the things that we've done fairly well I would I would say is that we over the last six months built up a pipeline not only clinical developments of our of with ketamine and other psychedelics but also the licenses that we have for the IP for delivering them the uses of them as well as formulations right and that takes manage a deal with experience so even for myself I've had 20 years experience in the biotech field specifically with clinical stage companies that are focused on novel drug delivering drug repurposing of drugs for FDA approval and I spent my career in senior business development so such as executing license agreements partnerships to strategic alliances and whatnot and I was the founder of several biotech companies now our R&D director Dr. Owen Van Canabra he brings a wealth of R&D experience for drugs with pharmaceutical companies experience as a research scientist with Eli Lowry Canada our scientific advisory board is very strong and actually continues to grow too with Dr. Robert Hauser from South Florida University as well as Dr. Alberto Espi from University of Cincinnati both are leaders in the field of Parkinson's disease and have significant experience in the clinical studies and drug approvals for Parkinson's we also have Dr. Dr. Joga who is a former FDA director and that participating in the drug approval process within the the institution Dr. Bev Inklingen who's a director of our pharma there he's a chief scientific officer for a company called Iron Shore Pharma which was recently been granted at the approval for a drug for ADHD so our board is also consists of drug development capital market expertise and business development and we're continuing as our company is growing as you can see with the recent news development to what now we are adding core competencies in drug and clinical development areas as well as now we're in the process of building our advisory team for our depression program which is very unique. Wow you guys are really building a strong team and for our community one of the key ingredients to finding a successful company is share structure it is vital for us we love tight float stocks it's one of the reasons we wanted to have you on our show you guys have a very tight float can you talk a little bit about your share structure and how much is held by insiders and institutions yeah absolutely I mean we have a good structure our insiders own nearly 25 percent of outstanding shares on institution I would say probably another 25 to even 40 percent and then we have I mean we have approximately 55 million shares outstanding 80 million fully diluted our market cap is roughly I think like 30 million which pales in comparison to other psychedelic pubcos if you will with valuations of 250 million even up to two billion Canadian market cap so but really in reality not many investors know about us you know we really put our head down and focus on expanding our product pipeline building out our intellectual property portfolio which is consistent with 19 passes of band applications that all compasses our micro-needle delivery technology and then you know we have licenses from from technologies originated from UCLA Queens University Belfast also Academy for Parkinson's from the University of Arizona also our combination formulation from the NHRI so you know with this validated IP if you will in our in our in a clear path for drug development you know we're very unique to the field and you know we're young in the sense of because we kept our head down not really been exposed in fact this is my first live interview since our inception so you know I felt like this is a great time for us we've had some milestones so it's a good time for investors to you know learn about our story because you know we are in the couple of our value being recognized and I'm just totally happy to share our story with you and your audience well our audience is worldwide so you are going to get people calling you I promise you that okay and we'll have some new potential investors and you will have some new potential business partners from this video because we have about 100 countries that will tune into this video oh awesome an investor wanted to get in contact with you or a shareholder joint venture partner anyone what's the best way for them to reach you Fabio yeah sure like I just you know I just want to build up on something that we're going on like I mean with our low I guess you could say ultra low valuation compared to our peers you know we are changing the way how psychedelic pharmaceuticals are being used through our myconeal delivery patch and our unique ketamine formulation that will hopefully revolutionize if you will how mental health neurological and pain disorders are treated you know we have a robust FDA clinical product pipeline soon we're going to have two FDA programs going to phase two clinical studies we have a broad patent portfolio which I mentioned making us one of the few companies to have a collection of these I guess you could say psychedelic assets to lead these you know the psychedelic renaissance that we seem to be in and again with our prolific team and our value proposition is only now starting to get some recognition with your audience worldwide and with our focus of getting our word out there since the psychedelic investment community I see tremendous upside potential for pharma there and its shareholders so I encourage anyone who's listening or down the road whatnot is to visit our website at pharma there.com I'm sure you'll have that on your page as well and on but you can also email me call me or you know email info at pharma there.com our investor's desk deck is available on our website which lists out all the IP that we have you can really do a deep dive on our company it's not you can understand what we're about what we're trying to do and how we back that up not only from a patent situation but from a clinical you can really dig dive deep on the scientific rationale and even research that's was done with our program so you know we look forward to updating our shareholders and our developments over and milestones over the next several months so you know I thank you for your time and you're interested in learning about pharma there and hope to see you know you just join the join with us on this journey that we're trying to achieve to you know have our common goal of just bringing psychedelics on the forefront for mental health and neurological pain disorders. Oh this is great we specialize here at Rich DV Live of finding companies that are undervalued, under-appreciated, underexposed and we bring them to the world by doing what we're doing right now you know getting a chance to speak directly to the person who created the company speaking to the founder getting a chance to see your passion about the industry getting a chance to understand the share structure getting a chance to understand the management team getting a chance to understand how to contact you this is how we've built and worked with every client that we've worked with and we've seen a lot of those clients go up a thousand percent and I don't see any reason why you also cannot be a huge success story in the next six to 12 months now one thing I want to make sure everyone understands about Rich DV Live is that we are not licensed advisors so always do your own due diligence always do your own research before you invest in anything that we talk about here at Rich DV Live go and speak to a financial advisor chances are when you speak to a financial advisor they're gonna say oh where'd you find this pic I like it I hear it every day guys because we literally have financial advisors joining our club because they want access to great companies like your company first and that's really what we specialize in we're not the people that panic when stocks are down in fact we're the ones that are the buyers when great companies are down and then when stocks are up like I said we're not beating our chest talking the world about how great we are we're selling and that's how we trade and and that's how I teach our investors to trade and in doing that we're able to build a lot of value for ourselves create a lot of wealth as a community and then when I bring the next undervalued pic to the community the community is in a cash position so they're typically ready to to buy I don't have to tell them what to buy everybody decides based on the value of the company what they want to buy and what they want to sell and when they buy and when they sell so I just want to make sure everybody knows that guys remember if you like this video please smash the like button comment down below share the video everywhere and subscribe fabio thank you so much for joining us we wish you all the best of luck in your future endeavors our entire community be watching you very closely and if you ever have any other big breaking news I'd love to invite you back on our show so we can talk about a live absolutely and I love to share our company as we evolve and I'm always available for any type of interview that you are so I appreciate your time and you learning about our company and your audience learning about our company myself and what we're trying to achieve hopefully resonates well again if you have any questions feel free to just reach out and and just just join us on this journey so thank you very much for everyone's time and have a great day thank you fabio for joining us everybody ph rm in canada it's already up ph rrf in america also up today if you're not winning you're not watching bring the winners and we bring them to you first thank you fabio keep up the great work have a great day thank you you guys for watching


Hi, everyone, and welcome to the Big Data Deep Dive with theCUBE here on EMC-TV. I'm Richard Schlesinger, and I'm here with Tech Industry Entrepreneur and Wikibon Analyst, Dave Vellante, and SiliconANGLE CEO and Editor-in-Chief, John Furrier, known as the anchors of the always popular and informative broadcast theCUBE. We are here to talk about Big Data in Science now, and welcome to you guys. Thanks for coming by. We've talked about Big Data in terms of every aspect of everyday life, but there's an obvious application for solving great scientific problems. There must be an awareness of that in the AlphaGeek community. There's some serious attention, and quite frankly intoxicating when you talk to these guys out there in the science field, because the two things going on right now that's affecting their world, and they're on top of it. There's no need for any kind of education there. High performance computing, Intel, Moore's law is getting better and better, more processing power, more stuff can be stored thanks to EMC, but now with Big Data, that's all the horsepower is at a crunch to data, so in space and in oil expeditions, things like that, it's just absolutely phenomenal. It's tailor-made, it seems to me, for science, which deals with great amounts of data. And John's right, high performance computing used to be this nitchie, yeah, only the science community used it, now it's going mainstream. So a lot of these concepts that were confined to the scientific community are now finding their way into mainstream Big Data, multiply that by 10, and that's the science community. So we found a group of astronomers. This is a fascinating contrast between old technology and new technology. For time and memorial, astronomers have been keeping track of the sky by recording stars on these sort of almost photographic-type glass plates that they have to store all over the world of millions of these things, couldn't be more old-fashioned. So now they're going to try to use Big Data to analyze those things and really get a more realistic idea of how the universe was born and how it's evolving. The project is called PARI, and watch this. How large is the universe? How did the universe begin? Could there be intelligent life out there? The information we need to answer all these big questions is really right in front of us. If we can harness that information, we can unlock the mysteries of the universe. Don Klein is the founder and CEO of the Pisgah Astronomical Research Institute, or PARI, located in North Carolina's Pisgah National Forest. This non-profit center for astronomical research and education is using the power of Big Data to show us the universe as we've never seen it before. Astronomy is all about observation. Now if we just look into the telescope, we can see what the sky looks like right now. But what really is interesting is to see how the sky has changed over a long period of time. Is the star getting brighter? Is the star still there? Is it moving? Fortunately, astronomers have been recording the night sky since the mid-1800s on photographic glass plates known as star plates. This is a plate from Mariah Mitchell Observatory in Nantucket Island, it was taken July 19, 1936, of a comet called Peltier right here. These fragile plates have been hidden away in basement archives for generations. That is, until now. This is Gamma 2. It's one of two high-precision digitizing machines that we have to scan our star plates. Perry is on a mission to digitize these 200,000 donated star plates into a massive online database so they can be accessed and analyzed by researchers around the world. Right now we have stored over one terabyte of star data in our database. Check Republic astrophysicist Dr. Rene Houdek is using the star plate database to help plan an upcoming European Space Agency mission. Set to launch in 2014, the ESA's Gaia spacecraft will use its one billion pixel digital camera to survey more than a thousand million stars. The main goal is to understand the universe, the origin of the universe. Rene is intrigued by gamma ray bursts he's found on the Perry plates and plans to have the Gaia spacecraft take a closer look at this rare phenomenon. He hopes that understanding these massive blasts of energy could someday help us develop a limitless energy source right here on Earth. And this is already something where we can learn a lot about the origin of the generation of energy. Back at Perry, the ultimate goal is to digitize all the world's estimated 5 million star plates. But at 2 gigabytes per plate, secure, reliable data storage is mission critical. We think it's important work and we want to make sure they have the right tools to get the job done. When EMC's Bob Hawkins learned this cash-strapped non-profit needed to beef up their data center, he knew he could help. Today, the Star Play Digital Archive runs on EMC donated starfish. It's all about big data, the ability to store that data in a secure and reliable environment, the ability to analyze it, and the ability to tease the full potential of the data. What we've done so far is just the tip of the iceberg. As we continue to build the digital database, we will open up untold opportunities for new research. The possibilities of what we can discover are endless. Wow, so two things struck me about that piece. One is they really got their work cut out for them. They've only just begun. And the second thing is, just because I'm so curious about this stuff, I can't wait to find out if they learn something, you know, earth shaking, so to speak. Yeah, so another area, Richard, is healthcare, right? And healthcare historically has not been an aggressive adopter of technology, but at the same time, big data has potentially huge transformative effects on the industry. Yeah, I mean, one of the things we'll have, Terrell Depp, my interview with him. I just want to show you this great video at Cassandra Summit, which is another alpha geek kind of big data conference. But what's interesting about this video is that Terrell talks about problems that he's solving in healthcare, which is, there are many problems to solve. There's database problems, there's government laws, HIPAA that prevents data from being shared, it's complicated. It's really complicated. But what he's focusing on is patient-led care. This is where the revolution of big data is all about, it's about the people. It's everything's people-centric. In this case, it's healthcare people-centric. So great video, he's changing the game. Again, another disruptor like Virginia in the previous video. So watch this video from Terrell, great video. We're back live here at the Cassandra Summit. I'm John Furrier, the founder of SiliconANGLE. I'm joined by my co-host. I'm Jeff Kelly, lead big data analyst from Wikibon. And we're joined here with Terrell Depp from Healthcare Anytime, CTO there. Welcome to theCUBE. It's your first time on theCUBE and we promise it'll be an enjoyable experience, right, John? Yeah, so our goal here is to really kind of get to the events and extract the signal from the noise. People want to know what's going on at Cassandra in the big data space. It's being debated, debates that range from proper language to use, no sequel versus sequel, relational databases, the latest shiny new toy, whatever that is, people like to talk about it. But really what we've found is big data is really changing business with mobile and with dashboards like the Nexus 7 and the iPad. Real-time analytics data, fast data to the edge of the network is really viable. And I'm excited to talk to you about that because what better place than the medical profession if you want to have information at your fingertips because it's life and death, it's not just business, doctors are on the field. So healthcare is a really viable space. So is big data a reality? That's my first question for you in the hospital space. Obviously tablets are relevant. Big data, what's the state of the union for big data there? Yeah, big data unfortunately is getting some pretty slow adoption. And I attribute that primarily to the kind of inside the box thinking. Healthcare is not known for its rapid technology adoption. As a result, new technologies are even slower to catch on. And when we start looking at solving problems in healthcare, we have to think very much outside the box. And you cannot take an individual patient and put them in a situation where the information you collect on them is the same as the patient that you saw previously. Every patient, every episode of care is going to be absolutely different. Even for the same problem, your heart attack and my heart attack may be completely different. Your follow-up visit is going to be different from my follow-up to visit. How do you take that data and put it into something that can be mined successfully so that you get decent analytics out of it? You simply can't put it into a traditional two-dimensional data model. And also, not all the records are digitized too, right? I mean, that's another problem, right? That's a completely separate problem. That's a problem that's more of a cultural problem. It goes back to the adoption of technology being very slow. In the hospital business, there's a lot of database work. And with HIPAA, regulations around data is a factor. Is that a factor, or is it not a factor, or is my- I don't know much about it, but that seems like it could be a factor. Well, anytime you're talking about regulations and compliance, it's going to be a factor. And for a company like Healthcare Anytime, it's a big factor. And it goes beyond just the clinical aspect, it goes into the financial aspect because we have to not only be HIPAA compliant, we also have to be PCI compliant. And getting that data, keeping that data secure, accessing that data in a timely manner, that's what big data is all about. So for our viewers out there who might not be that familiar with healthcare anytime, why don't you tell us about kind of what you guys do, what's your core product, and whether it's patient portals and kind of bringing in data from multiple sources. So tell our audience a little bit about what you guys do, and then maybe we can talk a little bit about kind of how you do it. Well, the core purpose for Healthcare Anytime's existence is for the purpose of satisfying the patient need. It's patient-facing healthcare. That's a market that has been grossly underutilized, underleveraged, mostly because there's no money in it. And part of the emphasis that the Obama administration has put on healthcare is to get that into the hands of the patient and make them more accountable. And that's where we come into play. Now, we're not newcomers to this environment by any means. We actually have 30 years of experience in the healthcare space as one of the top healthcare information service providers, systems vendors in the small and medium community hospital market. So this is something that is kind of a natural progression to us as we started looking at where is the gap, where is the opportunity, where is the outlier potential here. And so we look at it from a standpoint of patient engagement, which obviously starts with collecting information about the patient, getting them to pay their bill, and even engaging the patient's extended family and friends to get them more involved in accountability efforts and things like that. So the whole thing gets wrapped up into what's commonly called a patient portal. So let's talk about some of the real use cases of both your platform and just kind of healthcare, big data analytics and applications in general. I mean, what are we talking about? I think you have to take a look at what are the different stakeholders in healthcare. Obviously we have the patient and that's probably the most atomic level of care, a single episode of care being or visit to the doctor's office being the smallest, most atomic component. The patient is generally more interested in knowing, okay, what were the results of my most recent lab test? They're not as interested in the long-term perspective or the long-term view of their care like a doctor would be. Then you take another step out and you have a completely different perspective on the data in that you have a hospital or even a region that is interested in things that are peculiar to that region. Some areas have a higher rate of diabetes than other areas. Obesity is more common in certain areas than in other areas. Those regions want to look at the data in a very different way. Step it out a little bit further and you start looking at a national and international level and we have public health and immunization concerns and we want to know what's this next flu outbreak going to do and how do we project where the flu is headed next? How do we stop these things before they become financial catastrophes? Right, so it very much depends on their perspective. Exactly. Where are you coming from? Carl Chell, thanks for coming on the queue. We really appreciate it. You guys are in a growing market. Obviously this needs to be some transformation in health care and you guys are doing some good work there. Appreciate the time. What do you guys make of the fact that he said that the people in the health care industry are resisting this new technology? Well HIPAA notwithstanding, the more data that you can put in the hands of the patients when they're making critical health care decisions for themselves or their families, the better off the system will be. So how do you get the doctors? How do you get the industry to go along? I think one is having the data available. Step one, two is getting the iPads in front of the doctors. You know, we'll get the iPad, get a device in front of the doctors when they can see and touch the benefits which big data allow them to do. Things will change.  It's an Irish company and they were, let me just get this right. They have an index of 11 million trees on three continents and they've developed a system to a big data system to keep track of them to help meet the market demand, well, at the same time, minimizing the effect on the forest. So take a look at this. Our company has developed a radical new way to better measure forests. We started off with the basic idea of improving the way forests are measured. Up to now, forests have been measured with 19th century tools and measuring tapes and calipers. On average, 20% of the value of forest is lost at harvesting time. That value is lost mainly because the wrong logs are searched for a cut from the wrong forest. So what our system does is tries to show the forest owner and the sum of where the optimum logs are and where they are in the forest estate and cut them just in time. Keep that forest alive, keep that tree alive until it's optimum to fill that tree when the market really needs those logs that are in that forest. We've created a new system using 3D scanners. So the starting point is 3D scanners from the air from an aeroplane and on the ground with a 3D laser scanner. And we're the first company in the world that combines aerial scanning that looks down on the forest that gives you a macro view. What's the variation of trees across a wider cover of area? And then the ground sampling system is the terrestrial scanner where we go in and we actually scan sample plots to try and work out what's actually down on the ground. We've developed intelligent software then that takes this new information and creates a digital forest, a 3D forest. And that forest is stored in the cloud. Forest owner can type in the logs that the market currently wants and they can cut those logs and test all available forests out there across the resource which forest best suit that current market demand. It's bringing the world of lean manufacturing to the forestry supply chain. The old world was based on models and models are generally not ever totally correct. And with the analytic system that we have, we're able to do some new types of data mining and analysis to allow the forest owners to give real insight into the actual contents of the forest. We're only waking up to the whole power of big data. We've realized that there's a huge opportunity to capture masses amount of data from different parts of the world and use that data to work together with other forest owners to share data to be able to give insight at a global level. Foresters think at a national at a local level too much, whereas it's a global challenge. And that challenge is to try and keep that market supply but using as little forest as possible, trying to manage that forest as sustainably as possible. So big data and analytics is where that solution lies. It's about getting better information and analyzing that information, analyzing that data and to create new insight, new information and make better decisions. That's the real opportunity of big data and analytics. The missing link is this better information, this tackling this information problem of what is actually out there before harvest. We've developed a virtual harvesting machine that allows the forest owner and the sawmiller to go online after we scan, collect this better information and allow them to cut the forest online and see which forest yield the right amount of logs, the right types of logs and where are those logs in the forest? With our technology, we've proven that you can keep the markets applied but commit less trees. That can only be good for the planet, more wood from less trees. You know what I love about that video is that incredible giant machine ripping trees out, brute force, and yet we're talking about squeezing more productivity out of that process and you're seeing that in a lot of different industries, transportation and logistics and the like. Yeah, Dave, there's a trend out there if you call the Internet of Things where sensor networks, we talked earlier, this is just one example of the big data impact. It's not just what you think it is, it's everything possible is now changing and it's a beautiful thing. I love the Internet of Things and we'll have more on the Internet of Things. We're out of time now but we hope that you'll join us again. I'd like to thank you guys, John and Dave, for joining us again and sharing your insights and we'll have more installments of the big data deep drive coming up so be sure to stay tuned to the conversation with my new best friends from theCUBE right here on EMC TV.


The stereotypes that are mainly in small-holder tea farming is that women, the way women are perceived, they perceive that not able to achieve most things that men can achieve. So because of that, and because of the society, because the way they've been socialized, the women as well, they believe that kind of stereotypes that they cannot achieve as much as men achieve. And the men as well, because of the way they were socialized in that community, they believe that those stereotypes are real. So the way they conduct themselves, like the way they go about their business, they go about making those stereotypes reality for both men and women. So the women would look down on themselves, and the men would look down on the women, and the women, and that makes the women not able to fully participate in the commercial farming as fully as to their ability. Stereotypes are commonly everywhere in the world, each part of the world, each country have their own stereotypes, and in each country you find different areas in the same country having also different stereotypes about gender. So what we did as Warwick, we wanted to understand what sort of stereotypes are with the people that we're working with. The main reason of it was to understand how the women believe about themselves and how men perceive the women. So the gender audit was just to understand the stereotypes that would be broken, the progress of our work when we're doing gender mainstreaming in that area. So we had a set of questions that we asked for to both men and women of different ages, the Edari, the middle age, and also young. The questions were same to men and women. There were a lot of questions that surrounded the understanding of leadership on women and also whether the ability of women, how men perceive women in that society, whether they can be able to lead an association or they can lead a business, and how women perceive themselves, whether they are able. One of the most things that came out in the audit is that the women don't think that they can't lead or don't think that they are not able. They don't think that they cannot do as much as men do. But what brings them back is the same cultural beliefs that they have been socialized in, they are socialized to let the men go first. Even though a woman is more capable to take a leadership position, cultural socialization that she has is that you have to let the man go first. That's respect. That's your being a good woman. A woman would live out positions that they are able to do that, and they will give away opportunities and they will give away benefits that may work for themselves because of the belief that if I grab this, if I take this opportunity of a leadership opportunity, I am grabbing a man's opportunity because a man is supposed to be the leader of this. So this cultural socialization comes from that understanding that men are natural born leaders. They are leaders in the family, they are leaders in the society. So even if we have groups of farming, commercial farming groups, men are naturally leaders, even though some of them don't have the leadership qualities, but they'll just still be put in position because of the gender stereotypes that women are not born leaders, cannot lead. So we should put a man in the position. From the gender audit, Wallach worked with the results and tried to build any gaps that were there so that the women could believe themselves again to see that they can lead the associations that they have, the commercial associations they have, and also they can make decisions and contribute to the society. So that involved going through some gender mentorship sessions with the women and the whole of the association, the men as well. The reason we did with men was for them to understand the gender mainstreaming that it does not mean that women are taking over the positions of men. It just means that equality, like equity, you need to work together. Everybody is capable. If he's capable, put them in the right position beyond the agenda, beyond that this is a woman or beyond that this is a man. So we worked to encourage women's agency because when only men have the right to speak, only men have the right to make decisions. They are one way, they don't benefit everybody wholly. So when women are involved in that, when they see themselves that this is what we need, this is the development that we need to work for women. It works for both men and women because it's community development which has everybody involved in it, other than women being participants, but not making decisions just attending the sessions. So there's a difference when women have agency, it's their participation in making decisions that counts. The decision becomes more beneficial to the society and also more sustainable because they took part. It's different when they are participating, but they are just a crowd in the decision making. Wallach worked with men in the Suwazi community, mainly on gender mentorship as well as legal empowerment. So we use legal empowerment a lot to make the men understand that gender equality is a legal requirement for them to be in the same equity, same positions as women. So mainly we touched on that and to help them understand that because it's important for them to understand that we're not trying to change their culture. We're not trying to change the way their society is ordered or the way their society is leading, but it's important for them to understand how they're leading the society. It's important for them to understand the legal requirements that everybody has the responsibility to follow. So it helped them to see the reasons why the decision, the processes of decision making that they have to have a female perspective of it. So if they're making decisions about the community, making decisions about their farming association, what is the female perspectives to the benefits that they're trying to bring? The benefits that they're trying to bring only answering the men's problem or they're answering the female problem as well. So if they see the way that the decisions that we're making are answering both the men and women problems, the agency is much stronger that way because it is answering what the society needs. So it was easier for them to understand in that way that when we talk about gender equality and agency and legal empowerment, we mean that the answers to the problems are looking both at both genders are answering the problems of both genders.


Do we have free will or not? Many of you are going to disagree with what I'm going to say at least for the moment But in about a minute or two I'm going to ask you a question a challenge if you will and then we'll see if maybe you begin to change your thinking on what I'm Saying, literally speaking the Bible never says we have free will the term free will is never found in the Bible But does that mean that the notion or the concept of free will is not in there also or is it? When we say free will we mean volition or that man has the ability to choose what he wants to do So yes, man does have volition man does have will but is it free? We are in one of two categories We are either of our father the devil or we are sons of God of the Holy Spirit and therefore slaves to God There is no in between no third category. We are either one of the two We are either influence controlled or motivated by sin and Satan or We are controlled and motivated or influenced by the Holy Spirit One or the other so really a better term would be controlled constrained restrained limited or influenced will But not free will consider this when God says something is going to happen It's because he decrees it to happen not because he predicts it's going to happen And if he decrees something to happen, how then is God confident that it's going to come about? God is assured that what he decrees is going to come about because of his will. Ah, there it is God is the one who has free will God is the one who has a will that is not influenced or controlled by anything other than himself We can't say the same thing can we so think of it like this in this corner You have man five foot six foot whatever weighing 100 200 pounds with his will and in this corner We have God and his will now you tell me in this ring who was going to impose his will on the other Okay, I hear what you're saying Corey, but doesn't the Bible say that God is not willing that any man should perish But we know that some do and isn't that because of their own free will to leave to not choose God Well, that would make sense However, if we read carefully we discovered that the word for will is not the word the Greek word Philo, which means his own volition or his choosing it is the word Bulamai, which is that he has not determined or Planned for anyone to perish. So that makes a difference. And so God though He hasn't planned for anyone to perish those that come to him will do so as a result of his will But the next question is going to be does that mean that we are robots? Of course not. God does give us the ability to make choices and decisions However, he does so in a constrained confined area according to his will and if we don't Make the right decisions and choices within this confine or then he holds us accountable For those decisions that we make But if God has narrowly willed in some cases that this or that would happen and we decide that no I'm not going to do that. What do you think is going to happen? Well, I'll tell you what's going to happen. His will is going to be done Don't believe me ask Jonah the Bible is crystal clear on God causing all these things to work for his good for his glory And so that's why it's important that we also know that he is the one whose will is in control He is the one that has free will and ours are controlled Why is that important because then we can begin to give him glory for what he's done in our lives Our salvation is not so much a work of what we've done by our own hands, but because of what he's done So you still don't believe well in the future We're going to have some more in-depth studies on this particular topic Touching on God's sovereignty and his providence as as it relates to our salvation But I said earlier that I'm going to give you a question a challenge To see if maybe it might cause you to change your thinking or at least cause you to think a little bit more about this And so here's the question if you have free will meaning you can choose to do what you want to do and Your will is to not sin you choose not to sin then here's the question Why do you?


Well, good afternoon, ladies and gentlemen. I'm all to speak, let me say that first in a conference with such esteemed speakers like Mr. Constancer or Mr. Noonan this morning, of course the disadvantage of speaking at this hour is that much has been said already in the morning. The good thing, at least for me, is that I speak as the first of these four people, so I have a slight advantage still. And also, I apologize in advance that I'm not going to say too much about the asset goal to reviews, if you expect that, but if you have questions, of course I'm open to answering those afterwards. I was confronted with a different question with a seemingly straightforward topic to contemplate on in my short address. I was invited to express my views about the future of banking from a perspective of a core country. It turned out to be quite a challenging task though, because what I started to realize was that the Dutch perspective, and probably also my own, is becoming a critically European, getting closer to the perspective of our peers. So today I would like to explore the process of such evaluation and try together with you to take a glance at the future, which I believe to be our common future, the European future. So about this Dutch perspective, from a linguistic point of view, the countdown future is always, of course you should know, starting at the present moment, when with hindsight, with the present knowledge of our actions and achievements, we try to build plans that would lead us to our goals and aspirations, goals that are yet to be achieved. However, today, if you would bear with me for a moment, I would like to start the countdown of the future at almost half, one and a half year ago, which was, as you know, as already mentioned this morning, the moment on which the President of the European Council, Mr van Rompuy, presented a report on June 26, 2012, developed in cooperation with the President of the Commission, Eurogroup and European Central Bank, entitled Towards a Genuine Economic and Monetary Union, a report that was setting an EU-wide vision and action plan that would take perhaps over a decade to implement. The first cornerstone of this framework, and I'm going to say a bit more about that, which by today we are putting in its rightful place was the single supervisory mechanism, about which a lot has been said in the morning already. It is meant to address structural shortcomings in the institutional framework for bank supervision and financial stability, shortcomings that are particularly relevant for the Eurozone, where interdependencies resulting from the single currency are the most pronounced. So without looking forward to my own, I can confidently quote the mentioned report which deemed integrated Euro area banking supervision to be, and I quote, essential to ensure the effective application of potential rules, risk control and crisis prevention. So at that point, central banks of the Eurozone and national governments had a common interest, getting another pillar in place to support the monetary union, but perhaps still somewhat different perspectives. And supervisory authorities, whether separate or being within the central bank, like myself, were more of an object of the reform at that point in time than the steering wheel of it. But that has changed when the SSM preparations actually started at the ECB, involving all the national supervisors in the process directly. So together with the ECB, we were asked to develop the future supervisory model of the SSM in the so-called supervisory manual, Mr. Konstantino referred to that already, and the legal framework for cooperation between the ECB and the national competent authorities that the SSM would rely upon, the so-called framework regulation, which by the way will be publicly consultant as of January, as you might already know. We entered the scene, so talking about perspectives, I think we entered the scene all with our own distinct vision of what future Eurozone supervision would look like. And we discovered differences, slight and significant in how we conduct supervision at home. However, we all had one common goal in mind, to take the best practices and look for common approaches and build upon them to have a new, efficient and effective European model of supervision. I'm proud to say that although at the start each supervisor might have hoped that their model is the perfect one, and should by all means be taken over and elevated to the European level, we have come to realize that borrowing the best from our peers and creating something new is actually the right way forward. At home, we are yet to adjust to these new developments, but one year from the start of preparations, I dare to say a new Eurozone perspective on what a single supervisory mechanism should look like has emerged. About the comprehensive assessment and a few words. As you all know, of course, the ECB has just launched this exercise, the so-called comprehensive assessment, and again, a few things have been said about that already. It's an important starting point for the commencement of the Eurozone supervision. As a chair of the work stream that led to work on designing this comprehensive assessment and specifically the asset quality reviews, I had another chance to take a step back from the purely Dutch perspective on all this and concentrate on the framing of the Eurozone objectives and methodologies for the exercise. And risking to add even more complexity to the different perspectives on all this, I would like to try and take a look at this from the perspective of one of the most important stakeholders, the banking sector. Which is actually a question in my mind that I don't know how many bankers are in the room, because I've heard a lot of policymakers and central bankers and supervisors and people from the press. We have bankers as well. We're just talking about bankers. In the short term, back to the story, starting early in 2014, as you know, the Eurozone banks are facing execution of the asset quality reviews. It's no secret, I think, and people have been saying that all along that the project is bigger than probably any of us, at least most of us have ever done. Is it certainly true for myself? And all that in a tight timeframe with huge complexity and an unprecedented rigor. We have our supervisory objectives in mind, transparency, as has been said, regaining public and investor confidence in the sector, cleaning up the balance sheets, even recapitalization if needed. However, I'd like to think there's a lot in this for the banks themselves as well. Not only will they have the chance to regain the trust of markets, politicians, and the public, but also to get an insight into the resilience and soundness of their peers. Banks are each other's business partners. And currently, frankly, they have nearly the same degree of mistrust in each other as the public has in all of them. The comprehensive assessment may be burdensome, fair enough, but it's also a chance, a chance to set foot again on more solid ground for the banks. However, the SSM does not stop with the comprehensive assessment. Of course, it starts with it. So in 2014 and 15, together with the banks, we are facing implementation of this single supervisory mechanism and a transfer to direct supervision by the ECB, supported by us as local supervisors. Core elements of the SSM supervisory framework that will impact the banks do not end with changing the authority responsible for supervision. The institutional setup will finally reflect the cross-border character of the banking business. And we might start to see and hope true European banks. The very supervisory cultural imminently changes my strong conviction, characterized by our rigor, consistency, and intrusiveness. And more operationally, I don't want to bore you.  The crucial element of the new eurozone supervision is expected its data intensity to say it like that. But obviously, I think a huge reporting and IT impact on the banks. We should be mindful, at the same time, that in parallel with this important change in the institutional landscape, banks will need to migrate to Basel III and CD4 requirements. Capital and locator requirements with new regulatory elements introduced like the level ratio as well. And I'm strongly convinced that this is necessary, but it's certainly not an easy path to work on. Especially since the challenge will be, from my perspective, to increase buffers in times when the real economy recuperates only slowly and with a parallel need to not decrease or preferably increase lending to the real economy. So not an easy path indeed. I understand that I'm not looking too far into the future of banking. I hope that's not too disappointing. But 2014 and 15 will be very important years of transition to the SSM, and that is where the future, at least for eurozone banks, starts. Perhaps lastly, still contemplating the banking sector perspective, I would foresee and frankly hope and expect to see significant business moment change. I think it has been mentioned in the morning as well. Bankers should aim at building sound and safe banks again, aimed at supporting the real economy as retail, as a me, wholesale, and maybe even making markets. But not at designing and speculating with structured products, being true banks again, not asset managers, as some had de facto become. So the next step is developing business models, allowing banks to be a remain profitable long term, albeit under a tighter regulatory regime. The EBA has been mentioned in the morning as well. We started off with a vision over reform that is needed beyond the boundaries of the eurozone. So let's get back to that. It's important, by the way, to remind ourselves, as Mr. Konstantinov said as well, that the SSM is open to non-eurozone countries, of course, to join. But apart from that, the European banking sector will be functioning in an environment that is integrated by more than institutional reforms. It's supervision. I've already mentioned the CED-4 package that's been discussed in the morning as well. That will bring further convergence and harmonization of the regulatory landscape. And this single rulebook that has been mentioned before is being developed by the European banking authority, as you all know, is crucial for ensuring level play and field for the banks. The EBA, just as the ECB, and it's forgotten sometimes, I think, has a tremendous task, although over a different nature vested upon it. The CED-4 package envisages over 270 binding technical standards to be developed by the EBA. Among them, numerous standards in the areas of on funds, liquidity, credit and market risk, recovery and resolution planning, consumer protection, and so forth. Maybe it's a side step on consumer protection. I realize that in the morning, we mostly talk about the economy and the financial markets and the system and the banks. I don't think I heard, I might be wrong, I don't think I heard the word consumer, at least not much. Let's not forget about that dimension of all of this. A big part of, in the end, the thing that we all do it for. I would like to think. The EBA is already quite far in that process of developing these standards with the first batches of technical standards submitted to the European Commission for final endorsement. The EBA, back to this perspective thing again, the EBA is a member-driven organization, which means that we, the national supervisory authorities at the EBA table, are helping to develop this single rulebook for the whole EU. And maybe it's fair to say that it was at the EBA table on different stages of this process of developing European regulation that we learned to converge and compromise and hopefully synthesize our national views and sentiments in order to work in the interests of the European Union including our own countries and banking sectors, instead of just looking at our own local sector. So in other words, for regulatory purposes also, we are gradually evolving our perspectives to pave the way to European-wide thinking and European-wide goals. Hopefully the SSM will bring even more convergence also in this context. And we must by all means avoid, let's really cry of heart, avoid the vision into the Eurozone and non-Eurozone perspectives in Europe. We have a common goal to achieve, that's that genuine economic and monetary union that we keep mentioning today. So concluding, I hope these future challenges for banks and supervisors do not come across as a too gloomy picture. Maybe central bankers and supervisors do not have the reputation of being optimists. For me, I would rather like to think of it as constructive realism. I'm actually personally optimistic about the future of banking and banks in Europe. I'd like to say that banks had, have and will have a crucial role in the economy fostering and enabling growth. But it will be a different ballgame with new roles. And frankly, looking back at the last five to six years, it must be a different game. So with the single supervisory mechanism, we are making the first important step and visited in the report of Mr. van Rompuy. That I mentioned before, it is somewhat unfortunate, of course, we're talking about the future of banking here. It's somewhat unfortunate that we don't have a crystal ball predicting the future. I would have liked that also in preparing the speech. That would have at least give us a chance to take a peek at the future and to see whether we will succeed in the following steps. However, what we can do not having a crystal ball is work together with the banks, I would say, with a common vision of a sound and stable banking sector and with common means, the first of which is a single supervisory mechanism and make the future a little bit more predictable. Thanks for your attention.


Conservation and restoration of the Tapurum Temple by ITEC experts from ASI is a fine example of our cultural cooperation to preserve civilizational ties with Southeast Asia. It's a very challenging work where man-made structure and nature are living together. To tackle this complex project, the Indian Institute of Technology, Madras, also undertook some engineering and structural studies. IIT Madras is proud to be associated with the Ministry of External Affairs, Government of India in offering the ITEC program for professionals abroad.